Sildenafil (Generic) vs Vardenafil (Levitra/Staxyn): Cost and Access Head-to-Head

Why Cost and Access Matter When Choosing Between These PDE5 Inhibitors

Erectile dysfunction affects an estimated 30 million men in the United States, according to the National Institute of Diabetes and Digestive and Kidney Diseases [1]. Both sildenafil and vardenafil are FDA-approved phosphodiesterase type 5 (PDE5) inhibitors with well-established efficacy profiles. The clinical decision between them often comes down to cost, insurance coverage, and pharmacy availability rather than a dramatic difference in how well they work.

The PDE5 Inhibitor Class at a Glance

Sildenafil was the first PDE5 inhibitor approved by the FDA in 1998, based on the landmark Goldstein et al. Trial in the New England Journal of Medicine (N=532), which demonstrated that 69% of attempts at intercourse were successful with sildenafil versus 22% with placebo [2]. Vardenafil followed in 2003, with Porst et al. Showing significant improvements in erectile function for men with diabetes-related ED at doses of 10 mg and 20 mg [3]. The American Urological Association (AUA) guidelines list all PDE5 inhibitors as first-line pharmacotherapy for ED, without ranking one above another [4].

Where the Real Difference Shows Up

The pharmacological profiles are similar. Both drugs inhibit PDE5 in corpus cavernosum smooth muscle. Sildenafil has a T-max of about 60 minutes and a half-life of 3 to 5 hours [5]. Vardenafil has a T-max of 60 minutes and a half-life of 4 to 5 hours [6]. The meaningful gap between these two medications is what patients actually pay at the pharmacy counter.

Generic Sildenafil Pricing: The Low-Cost Leader

Generic sildenafil is among the least expensive branded-equivalent ED medications available in the U.S. Today. Teva Pharmaceuticals launched the first authorized generic of Viagra in December 2017, and more than 15 generic manufacturers now produce sildenafil citrate tablets [7].

Retail Price Ranges by Dose

A 30-tablet supply of sildenafil 20 mg (often prescribed as multiple tablets per dose for ED, though the 20 mg strength is FDA-labeled for pulmonary arterial hypertension under the brand Revatio) can cost as little as $9 to $15 at major chain pharmacies with a discount coupon [5]. The 50 mg and 100 mg tablets, which carry the ED-specific labeling, typically range from $0.50 to $3.00 per tablet with a coupon or discount card.

The 20 mg Workaround

Many prescribers write sildenafil 20 mg and instruct patients to take multiple tablets because the 20 mg strength, approved for pulmonary arterial hypertension, often has lower copays and fewer prior-authorization requirements than the 50 mg or 100 mg ED-labeled doses [8]. A meta-analysis by Yuan et al. Confirmed dose-response efficacy across the 25 to 100 mg range, with higher doses producing incrementally greater improvements in International Index of Erectile Function (IIEF) scores [9]. This prescribing strategy can reduce out-of-pocket costs by 50% to 80%.

Medicare and Medicaid Considerations

Medicare Part D plans generally exclude ED medications from coverage under the Social Security Act, Section 1860D-2 [10]. Medicaid coverage varies by state. Some state Medicaid programs cover sildenafil for pulmonary arterial hypertension but not for ED. Patients relying on federal insurance programs often pay full cash price, making the low generic cost of sildenafil especially important.

Generic Vardenafil Pricing: Higher but Falling

Vardenafil's patent field kept generics off the market longer than sildenafil. Generic vardenafil film-coated tablets became available in the U.S. In 2018 after Par Pharmaceutical (an Endo International subsidiary) and several other manufacturers received FDA approval [6].

Current Pricing Field

Generic vardenafil 20 mg tablets typically cost $3.00 to $15.00 per tablet at retail pharmacies with a discount coupon. That is roughly 3 to 10 times more expensive than equivalent-dose generic sildenafil. Brand-name Levitra, where still stocked, can exceed $60 per tablet [11]. Staxyn (vardenafil orally disintegrating tablet, 10 mg) remains a branded product without a generic equivalent as of 2026 and can cost $40 to $70 per tablet.

Why Vardenafil Costs More

Fewer manufacturers produce generic vardenafil compared to sildenafil. Market competition is the primary driver of generic drug pricing, as demonstrated by FDA research showing that prices drop to approximately 20% of brand cost only after five or more generic competitors enter the market [12]. Sildenafil has crossed that threshold. Vardenafil has not reached the same level of generic competition.

Staxyn: A Unique Formulation at a Premium

Staxyn uses an orally disintegrating tablet (ODT) formulation that dissolves on the tongue without water. The ODT format has faster absorption than conventional vardenafil tablets when taken without food, reaching peak plasma levels approximately 15 minutes earlier in some pharmacokinetic studies [6]. That convenience comes at a steep cost premium, and no generic ODT version is currently available in the United States.

Insurance Coverage Comparison

Insurance formularies treat these two medications differently, and understanding that difference can save patients hundreds of dollars per year.

Commercial Insurance Plans

Most large commercial insurers place generic sildenafil on Tier 1 (preferred generic), with copays typically ranging from $0 to $15 per fill. Generic vardenafil more often lands on Tier 2 or Tier 3, with copays of $15 to $50 [13]. Prior authorization is common for both medications under ED-specific coverage, as many plans limit quantities to 6 to 12 tablets per month.

Quantity Limits and Step Therapy

A 2019 analysis published in the Journal of Sexual Medicine found that 73% of commercial plans imposed quantity limits on PDE5 inhibitors, and 41% required step therapy starting with sildenafil before covering alternative PDE5 inhibitors [14]. This means patients who want vardenafil may first need to try and fail sildenafil. The requirement adds time and documentation to the prescribing process.

VA and TRICARE Coverage

The Department of Veterans Affairs National Formulary includes sildenafil as a preferred agent for ED [15]. Vardenafil is available as a non-formulary option that requires additional clinical justification. TRICARE follows a similar tiering structure, with sildenafil placed on the preferred tier [16].

Pharmacy Availability and Access Channels

Where and how patients fill their prescriptions can significantly affect both cost and convenience.

Brick-and-Mortar Pharmacies

Generic sildenafil is stocked at virtually every retail pharmacy in the United States, including CVS, Walgreens, Walmart, and independent pharmacies. Generic vardenafil has more variable stocking. Smaller pharmacies may not carry it routinely and might need to special-order it, adding 1 to 3 days to fill time.

Mail-Order and Digital Pharmacies

Mail-order pharmacies such as Express Scripts, CVS Caremark, and OptumRx often provide 90-day supplies at reduced copays. Both sildenafil and vardenafil are available through these channels. Direct-to-consumer telehealth platforms have expanded access to both medications, frequently bundling consultation fees with prescription costs. The FDA requires that all online pharmacies dispensing prescription medications be licensed in the patient's state of residence [17].

340B and Patient Assistance Programs

Pfizer's patient assistance program previously covered brand-name Viagra for qualifying uninsured patients, but the program was restructured after generic entry. No major manufacturer-sponsored patient assistance programs currently exist for generic sildenafil or generic vardenafil. Safety-net clinics participating in the 340B Drug Pricing Program can acquire both generics at steep discounts and pass those savings to qualifying patients [18].

Clinical Efficacy: Do You Get What You Pay For?

A common concern among patients is whether the cheaper option works as well. The clinical evidence suggests both drugs are effective, with no clear winner in head-to-head data.

Direct Comparison Data

A meta-analysis by Chen et al. Published in the International Journal of Impotence Research evaluated 82 randomized controlled trials of PDE5 inhibitors and found no statistically significant difference in IIEF-EF domain score improvements between sildenafil 100 mg and vardenafil 20 mg [19]. Both produced mean improvements of 7 to 9 points on the IIEF-EF scale. Giuliano et al. Conducted a crossover preference study and found that patient preference between sildenafil and vardenafil was roughly evenly split, with 45% preferring sildenafil, 41% preferring vardenafil, and 14% having no preference [20].

Onset and Duration Differences

Sildenafil onset ranges from 30 to 60 minutes, with effects lasting 4 to 6 hours [5]. Vardenafil onset is comparable at 25 to 60 minutes, with effects lasting 4 to 5 hours [6]. High-fat meals delay sildenafil absorption more significantly than vardenafil absorption, which may matter for patients who prefer taking their medication with dinner. A pharmacokinetic study by Rajagopalan et al. Showed that a high-fat meal reduced sildenafil C-max by 29%, while vardenafil C-max decreased by only 18% under similar conditions [21].

Side Effect Profiles

Both drugs share class-related side effects: headache, flushing, nasal congestion, and dyspepsia. Sildenafil is more likely to cause transient visual disturbances (blue-tinted vision) due to cross-reactivity with PDE6 in retinal photoreceptors [5]. Vardenafil carries a specific warning about QTc prolongation and should be avoided in patients taking Class IA or Class III antiarrhythmics [6]. Neither side-effect profile is severe enough to drive most cost-access decisions, but clinicians should factor in a patient's cardiac medication list.

Who Should Pick Sildenafil? Who Might Prefer Vardenafil?

The decision tree is straightforward for most patients. Cost sensitivity points strongly toward sildenafil.

Sildenafil Is the Better Value When

The patient has no contraindication to sildenafil, is cost-conscious, has insurance with step-therapy requirements, or needs a medication widely available at any pharmacy. The AUA's 2018 ED guideline update reinforces that PDE5 inhibitor choice should incorporate patient preference, side effects, and cost [4].

Vardenafil May Be Worth the Premium When

The patient experiences significant food-related absorption issues with sildenafil, needs the Staxyn ODT format for convenience or difficulty swallowing, or has tried sildenafil without adequate response. Switching between PDE5 inhibitors is supported by evidence: a study by McMahon published in the Journal of Sexual Medicine found that 62% of sildenafil non-responders responded to a different PDE5 inhibitor [22].

Starting the Conversation with a Provider

Patients should bring their insurance formulary information to ED consultations. Knowing whether a plan covers sildenafil at Tier 1 versus vardenafil at Tier 2 can save the prescriber time and the patient money. For uninsured patients, generic sildenafil at $0.30 to $1.00 per tablet is difficult to justify passing over unless a specific clinical reason warrants vardenafil.

Regulatory and Patent Field in 2026

The generic market for both medications has matured, but ongoing patent and regulatory developments continue to shape access.

Sildenafil Patent Status

Pfizer's core sildenafil patent (U.S. Patent No. 5,250,534) expired in 2012, and the method-of-use patent for ED expired in 2020 [7]. The generic market is fully open, with no remaining patent barriers. The FDA's Orange Book lists more than 15 approved ANDA holders for sildenafil citrate tablets [7].

Vardenafil Patent Status

Bayer's primary vardenafil patent expired in 2018, enabling generic entry. The Staxyn ODT formulation retains certain formulation patents that have limited generic competition in that specific dosage form [6]. Generic film-coated vardenafil tablets are available from Par Pharmaceutical, Macleods, and several other manufacturers.

Biosimilar and Novel Formulation Pipelines

No biosimilar pathway applies to small-molecule PDE5 inhibitors. Novel topical and intranasal PDE5 inhibitor formulations are in various stages of clinical development, though none have reached the U.S. Market as of mid-2026 [23]. These future products could reshape the cost-access comparison if they offer faster onset or reduced systemic side effects.

Cost Summary Table

| Factor | Generic Sildenafil | Generic Vardenafil | Staxyn (Brand ODT) | |---|---|---|---| | Price per tablet (cash, with coupon) | $0.30 to $3.00 | $3.00 to $15.00 | $40 to $70 | | Typical insurance tier | Tier 1 | Tier 2 or 3 | Tier 3 or excluded | | Generic manufacturers (U.S.) | 15+ | 3 to 5 | None | | Prior authorization frequency | Common | Common | Very common | | Mail-order availability | Universal | Widely available | Limited | | 340B pricing available | Yes | Yes | Limited | | Medicare Part D coverage | Generally excluded for ED | Generally excluded for ED | Generally excluded |

The annual cost difference is substantial. A patient taking 8 tablets per month would pay roughly $29 to $288 per year for generic sildenafil versus $288 to $1,440 per year for generic vardenafil. For brand Staxyn, that same usage pattern would cost $3,840 to $6,720 annually.

Vardenafil 20 mg carries a labeled QTc prolongation risk, and prescribers should obtain a baseline ECG for patients on antiarrhythmic therapy before initiating treatment [6].